

There is 1 credit hour available for the course and it will take approximately 1 hour to complete.

The curriculum will cover:

Title of Session

Case Discussion: Implementing Pharmacogenomics to Promote Medication Regimen Optimization of Opioids

Program Faculty

Joshua Russell, PharmD, PGY2 Pharmacogenomics Pharmacy Practice Resident

Hardware and Software Requirements

Absorb LMS does not have any specific system requirements and will display on a multitude of devices. The learner interface runs on screens of all sizes. Internet Explorer 11 and higher, along with the latest versions of Google Chrome, Safari, Edge, and Firefox are the supported browsers.

Important Note

Absorb does not support running the application, Absorb LMS, in multiple browsers or windows/tabs concurrently. Doing so may result in unexpected behavior. Manipulating browser cookies can cause issues with the normal execution of the LMS operations.

Also, your course content may have additional requirements beyond the browser.

Continuing Education Credits

You need to view the entire program to receive credit (approximately 1 hour total). You will then be directed to a post-assessment and an evaluation. To receive credit, you will need to correctly answer 80% of the questions on the post-assessment. Upon completion of the evaluation and successful completion of the post-assessment, a certificate will be available for you to print. You will have three attempts to successfully complete the post-assessment.

Pharmacist and Pharmacy Technician Credit

- Tabula Rasa HealthCare is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This live material *Case Discussion: Implementing Pharmacogenomics to Promote Medication Regimen Optimization of Opioids*, is assigned Universal Activity Number (UAN) #JA4008180-0000-21-157-L01-P and #JA4008180-0000-21-157-L01-T (Pharmacy Tech) and is accredited for 1.0 hour(s) for completion of all CE sessions. Term of approval is from this date on May 31, 2022 until May 31, 2023. *Case Discussion: Implementing Pharmacogenomics to Promote Medication Regimen Optimization of Opioids* is a knowledge-based CE activity.
- Pharmacist and Pharmacy Technician credit will be posted to the NABP CPE Monitor.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Tabula Rasa HealthCare University. TRHCU is accredited by the ACCME to provide continuing medical education for physicians.

Tabula Rasa HealthCare University designates this live material for a maximum of 1.0 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only credit commensurate with the extent of their participation in the activity. AAPA accepts AMA category 1 credit for the PRA from organizations accredited by ACCME.

Nurse CE

- Tabula Rasa HealthCare University designates this activity for 1.0 contact hours for nurses. Nurses should claim only credit commensurate with the extent of their participation in the activity.

Nurses licensed in Iowa and California: This activity was planned and developed in accordance with the continuing education standards of the American Nurses Credentialing Center (ANCC). The Iowa Board of Nursing and the California Board of Nursing will honor ANCC continuing education credits for face-to-face programs held outside Iowa and California, or for ANCC-approved online recorded courses taken in a self-study format.

Joint Accreditation Statement



In support of improving patient care, Tabula Rasa HealthCare University is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE Credit Statement



This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Conflicts of Interest

TRHCU requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose all financial relationships with any ineligible companies that they have had over the past 24 months. All identified relationships with ineligible companies are thoroughly vetted to determine if they are relevant to the activity and resolved according to TRHCU policy. TRHCU is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

The faculty members have no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers

The TRHCU planners and managers for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Financial Support

This program is not supported by any commercial or financial interest.

Privacy and Confidentiality Policy

We respect, and are committed to protecting, your privacy. We will not sell your personally identifiable information to anyone. You may read the Tabula Rasa HealthCare Privacy Policy on the TRHC website.

Questions?

If you have any questions, please send via E-mail to: learn@TRHC.com

Target Audience

This activity is intended for prescribers, nurses, and pharmacists and pharmacy technicians engaged in the care of all patients in the outpatient setting.

Overall Educational Objectives:

Case Discussion: Implementing Pharmacogenomics to Promote Medication Regimen Optimization of Opioids

After completing this educational activity and the post-test, participants should be able to:

Objectives for Doctors, Pharmacists, Nurses:

- Explain the role of drug-metabolizing enzymes in the efficacy and safety of opioids
- Review the 2021 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines Clinical Pharmacogenetics Implementation for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy
- Describe the clinical impact and benefit of pharmacogenomic (PGx) testing for opioids
- Apply PGx principles to patient case scenarios to showcase safer and more effective use of opioids in older adults

Objectives for Pharmacy Technicians:

- Explain the role of drug-metabolizing enzymes in the efficacy and safety of opioids
- Describe the clinical impact and benefit of pharmacogenomic (PGx) testing for opioids